bluebird bio Valuation
Is BLUE * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BLUE * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BLUE *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BLUE *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BLUE *?
Other financial metrics that can be useful for relative valuation.
What is BLUE *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$198.52m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 15.1x |
Enterprise Value/EBITDA | -2.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BLUE *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 8.9x | ||
MGNX MacroGenics | 6.3x | 25.5% | US$320.7m |
CRVO CervoMed | 24.6x | 40.4% | US$201.1m |
PROB Probi | 3.8x | 7.1% | kr2.3b |
LAB B Genomma Lab Internacional. de | 1x | 8.2% | Mex$15.7b |
BLUE * bluebird bio | 9.1x | 40.7% | Mex$198.5m |
Price-To-Sales vs Peers: BLUE * is expensive based on its Price-To-Sales Ratio (9.1x) compared to the peer average (8.9x).
Price to Earnings Ratio vs Industry
How does BLUE *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: BLUE * is good value based on its Price-To-Sales Ratio (9.1x) compared to the Global Biotechs industry average (10.2x).
Price to Sales Ratio vs Fair Ratio
What is BLUE *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 9.1x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BLUE *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$17.50 | Mex$68.29 +290.2% | 60.3% | Mex$134.50 | Mex$16.81 | n/a | 12 |
May ’25 | Mex$16.24 | Mex$67.44 +315.3% | 60.3% | Mex$132.84 | Mex$16.60 | n/a | 12 |
Apr ’25 | n/a | Mex$70.44 0% | 59.3% | Mex$133.27 | Mex$16.66 | n/a | 12 |
Mar ’25 | n/a | Mex$81.84 0% | 38.3% | Mex$137.67 | Mex$34.42 | n/a | 11 |
Feb ’25 | n/a | Mex$81.84 0% | 38.3% | Mex$137.67 | Mex$34.42 | n/a | 11 |
Jan ’25 | n/a | Mex$78.88 0% | 37.9% | Mex$136.26 | Mex$34.06 | n/a | 10 |
Dec ’24 | n/a | Mex$126.37 0% | 40.3% | Mex$228.12 | Mex$52.64 | n/a | 12 |
Nov ’24 | n/a | Mex$124.76 0% | 34.4% | Mex$193.27 | Mex$52.71 | n/a | 12 |
Oct ’24 | n/a | Mex$124.76 0% | 34.4% | Mex$193.27 | Mex$52.71 | n/a | 12 |
Sep ’24 | n/a | Mex$126.24 0% | 32.4% | Mex$188.59 | Mex$51.43 | n/a | 11 |
Aug ’24 | n/a | Mex$121.58 0% | 30.5% | Mex$167.18 | Mex$50.15 | n/a | 11 |
Jul ’24 | Mex$57.50 | Mex$121.45 +111.2% | 29.1% | Mex$171.27 | Mex$51.38 | n/a | 11 |
Jun ’24 | n/a | Mex$122.87 0% | 29.8% | Mex$175.53 | Mex$52.66 | n/a | 11 |
May ’24 | n/a | Mex$120.96 0% | 31.7% | Mex$179.80 | Mex$53.94 | Mex$16.24 | 11 |
Apr ’24 | Mex$54.00 | Mex$123.03 +127.8% | 30.7% | Mex$180.93 | Mex$72.37 | n/a | 10 |
Mar ’24 | Mex$98.71 | Mex$137.83 +39.6% | 26.5% | Mex$187.95 | Mex$75.18 | n/a | 9 |
Feb ’24 | n/a | Mex$137.83 0% | 26.5% | Mex$187.95 | Mex$75.18 | n/a | 9 |
Jan ’24 | n/a | Mex$142.61 0% | 30.2% | Mex$194.47 | Mex$58.34 | n/a | 9 |
Dec ’23 | n/a | Mex$142.61 0% | 30.2% | Mex$194.47 | Mex$58.34 | n/a | 9 |
Nov ’23 | n/a | Mex$150.58 0% | 31.3% | Mex$199.30 | Mex$59.79 | n/a | 9 |
Oct ’23 | n/a | Mex$154.91 0% | 31.9% | Mex$199.18 | Mex$59.75 | n/a | 9 |
Sep ’23 | Mex$120.00 | Mex$146.86 +22.4% | 34.0% | Mex$200.26 | Mex$60.08 | n/a | 9 |
Aug ’23 | Mex$78.00 | Mex$150.77 +93.3% | 48.4% | Mex$285.23 | Mex$40.75 | n/a | 10 |
Jul ’23 | n/a | Mex$145.84 0% | 51.4% | Mex$278.42 | Mex$39.77 | Mex$57.50 | 9 |
Jun ’23 | n/a | Mex$145.84 0% | 51.4% | Mex$278.42 | Mex$39.77 | n/a | 9 |
May ’23 | n/a | Mex$161.00 0% | 42.0% | Mex$285.72 | Mex$61.23 | n/a | 9 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.